Nuwellis Expands Critical Care Reach with Atrility Medical Deal…

Event summary

Nuwellis and Atrility Medical entered a co-promotion and distribution agreement for the AtriAmp® device on August 25, 2026.
Initial six-month pilot covers nine Western and five Southeastern U.S. states, with Nuwellis receiving commissions on sales.
AtriAmp is an FDA-cleared device for temporary epicardial pacing wires, complementing Nuwellis' pediatric and critical care portfolio.
Successful pilot could lead to Nuwellis becoming Atrility's exclusive U.S. distributor for nationwide growth.

The big picture

Nuwellis' deal with Atrility Medical aligns with its strategy of expanding its critical care portfolio through complementary technologies. The agreement allows Nuwellis to tap into the postoperative cardiac care market without significant incremental commercial infrastructure, leveraging its established relationships in pediatric and adult critical care. This move reflects broader industry trends of medical technology companies seeking capital-efficient growth through strategic partnerships rather than organic development.

What we're watching

Commercial Execution: How Nuwellis leverages its existing commercial infrastructure to drive AtriAmp adoption and recurring revenue.
Market Expansion: The pace at which Nuwellis can transition from pilot to nationwide distribution under the agreement.
Strategic Fit: Whether the AtriAmp integration strengthens Nuwellis' value proposition in pediatric and critical care markets.